Evidence map›Paper›PMID 29056333›Full record

ArticleStem cell reports2017

The Spindle Assembly Checkpoint Is Required for Hematopoietic Progenitor Cell Engraftment.

Andreas Brown, Johannes Pospiech, Karina Eiwen, Darren J Baker, Bettina Moehrle, Vadim Sakk, Kalpana Nattamai, Mona Vogel, Ani Grigoryan, Hartmut Geiger

Open access · goldAbstract read
In one paragraph

Article in Stem cell reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Andreas BrownInstitute of Molecular Medicine, Ulm University, Ulm 89081, Germany.
Johannes PospiechInstitute of Molecular Medicine, Ulm University, Ulm 89081, Germany.
Karina EiwenInstitute of Molecular Medicine, Ulm University, Ulm 89081, Germany.
Darren J BakerDepartment of Pediatric and Adolescent Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.
Bettina MoehrleInstitute of Molecular Medicine, Ulm University, Ulm 89081, Germany.
Vadim SakkInstitute of Molecular Medicine, Ulm University, Ulm 89081, Germany.
Kalpana NattamaiDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH, USA.
Mona VogelInstitute of Molecular Medicine, Ulm University, Ulm 89081, Germany.
Ani GrigoryanInstitute of Molecular Medicine, Ulm University, Ulm 89081, Germany.
Hartmut GeigerInstitute of Molecular Medicine, Ulm University, Ulm 89081, Germany; Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH, USA. Electronic address: hartmut.geiger@uni-ulm.de.
Universität Ulm · DEMayo Clinic · USUniversity of Cincinnati · US

Funding

Cdc42, hematopoietic stem cell polarity, and cell fateR01DK104814 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI ZHENG, YI · 2016 to 2019
$2.0M
Lineage Determination and Tissue HomeOstasis in the aged Hematopoietic SystemR01AG040118 · NIA · CINCINNATI CHILDRENS HOSP MED CTR · PI GEIGER, HARTMUT, ZHENG, YI · 2011 to 2015
$1.7M
Blood stem cell aging and biomarker studiesR01HL134617 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI GEIGER, HARTMUT, ZHENG, YI · 2016 to 2019
$1.6M
Genetic Reg. of Hematopoietic Stem Cell MobilizationR01HL076604 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI GEIGER, HARTMUT · 2004 to 2007
$1.2M
Stem cell aging and biomarker studiesR56AG050650 · NIA · CINCINNATI CHILDRENS HOSP MED CTR · PI GEIGER, HARTMUT, ZHENG, YI · 2015 to 2015
$390k
NHLBI NIH HHS R01 HL076604NHLBI NIH HHS R01 HL134617NIA NIH HHS R01 AG040118NIA NIH HHS R56 AG050650NIDDK NIH HHS R01 DK104814
6 · The paper itself

Abstract

The spindle assembly checkpoint plays a pivotal role in preventing aneuploidy and transformation. Many studies demonstrate impairment of this checkpoint in cancer cells. While leukemia is frequently driven by transformed hematopoietic stem and progenitor cells (HSPCs), the biology of the spindle assembly checkpoint in such primary cells is not very well understood. Here, we reveal that the checkpoint is fully functional in murine progenitor cells and, to a lesser extent, in hematopoietic stem cells. We show that HSPCs arrest at prometaphase and induce p53-dependent apoptosis upon prolonged treatment with anti-mitotic drugs. Moreover, the checkpoint can be chemically and genetically abrogated, leading to premature exit from mitosis, subsequent enforced G1 arrest, and enhanced levels of chromosomal damage. We finally demonstrate that, upon checkpoint abrogation in HSPCs, hematopoiesis is impaired, manifested by loss of differentiation potential and engraftment ability, indicating a critical role of this checkpoint in HSPCs and hematopoiesis.

Indexed as

M Phase Cell Cycle CheckpointsAnimalsAntimitotic AgentsApoptosisCells, CulturedHematopoiesisHematopoietic Stem CellsMiceMice, Inbred C57BLTumor Suppressor Protein p53Antimitotic AgentsTumor Suppressor Protein p53genome stabilityhematopoiesishematopoietic progenitor cellshematopoietic stem cellsmicronucleimitotic checkpointreversineSACspindle assembly checkpoint

Identifiers

PMID29056333
PMCPMC5830991
OpenAlexW2765686515

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.